<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579408</url>
  </required_header>
  <id_info>
    <org_study_id>CAP LDLT</org_study_id>
    <nct_id>NCT02579408</nct_id>
  </id_info>
  <brief_title>Quantifying Steatosis in Liver Transplant Donors</brief_title>
  <official_title>Controlled Attenuation Parameter for the Evaluation of Donor Steatosis in Living Donor Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic fatty liver disease is the most common chronic liver disease in Hong Kong. Its&#xD;
      presence among donors of living donor liver transplants could affect the outcomes of&#xD;
      recipients of liver transplantation. By using controlled attenuation parameter (CAP)&#xD;
      measurements, the investigators aim to investigate the association of CAP measurements and&#xD;
      severity of fatty liver among liver donors in the recipient outcomes of living donor liver&#xD;
      transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Living donor liver transplantation (LDLT) has been increasing worldwide due to the critical&#xD;
      shortage of cadaveric donors and the rising number of patients awaiting liver&#xD;
      transplantation. The long-term survival rates of LDLT are now comparable to that of deceased&#xD;
      donor liver transplantation. Currently, two-thirds of all liver transplants performed in Hong&#xD;
      Kong are LDLT.&#xD;
&#xD;
      The ultimate goal of LDLT is to guarantee donor safety while optimizing the best possible&#xD;
      recipient outcome. Donor liver steatosis is a well-known factor which could influence graft&#xD;
      function and long-term outcomes of the recipient allograft, and also affects donor hepatic&#xD;
      recovery. When needed, pre-operative liver biopsy is often used for the quantitative&#xD;
      assessment of donor steatosis, with LDLT not recommended when steatosis exceeds 30%.&#xD;
      Nonetheless, liver biopsy is limited by its invasive nature, sampling error and&#xD;
      intra-observer variations. Imaging evaluation for the quantification of steatosis via&#xD;
      ultrasonography or computed tomography also has various pitfalls. There is currently no&#xD;
      universal consensus on the ideal method in assessing donor steatosis.&#xD;
&#xD;
      Controlled attenuation parameter (CAP) is a novel non-invasive method to quantify hepatic&#xD;
      steatosis using ultrasonic attenuations to postulate fat content. It has been demonstrated to&#xD;
      have good correlation with the degree of hepatic steatosis in both Western and Asian&#xD;
      populations. The investigators aim to evaluate the application of CAP in the donor workup of&#xD;
      LDLT and to investigate for its association with post-transplant outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recipient allograft short-term outcomes</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Includes:&#xD;
Intraoperative parameters (blood transfusion, operation time etc)&#xD;
Postoperative outcomes (ICU stay, hospital stay, hospital mortality, major postoperative complication etc) Initial poor function, defined as an AST or ALT &gt;1,500 U/L on two consecutive measurements within the first 72 hours Primary graft nonfunction, defined as poor function of allograft culminating in either death of recipient or retransplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recipient allograft long-term outcomes</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Includes:&#xD;
Overall survival&#xD;
Primary graft nonfunction up to 1 year&#xD;
Liver stiffness measurements via transient elastography at 1 year&#xD;
Controlled attenuation parameter measurements at 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of controlled attenuation parameter scores with clinical parameters of LDLT donor</measure>
    <time_frame>At time of transplant</time_frame>
    <description>Correlation of controlled attenuation parameter measurements with:&#xD;
Body mass index (in kg/m2)&#xD;
Waist circumference (in cm)&#xD;
Liver volumetry and fat quantification via pre-operative computed tomography. Fat quantification is calculated by the hepatic attenuation measurement&#xD;
Donor histological grading of steatosis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Evidence of Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>LDLT donor</arm_group_label>
    <description>Donors of living donor-related liver transplantation</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and plasma for storage in anticipation of future biomarkers for the prediction of&#xD;
      improved post-transplant outcomes&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Donors of living donor liver transplantation conducted in Queen Mary Hospital, Hong Kong&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-60 LDLT donor who has completed donor workup&#xD;
&#xD;
          -  Consents to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant liver disease, including chronic hepatitis B and C infection, autoimmune&#xD;
             hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson disease,&#xD;
             and increased alcohol intake (30g per week for male, 20g per week for female).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wai Kay Seto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wai Kay Seto, MD</last_name>
    <phone>+85222553994</phone>
    <email>wkseto@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Medicine and Department of Surgery, The University of Hong Kong, Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wai-Kay Seto, MD</last_name>
      <phone>+85222553994</phone>
      <email>wkseto@hku.hk</email>
    </contact>
    <investigator>
      <last_name>Wai-Kay Seto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth SH Chok, FRCS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Fung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 14, 2015</study_first_submitted>
  <study_first_submitted_qc>October 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Wai-Kay Seto</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>LDLT</keyword>
  <keyword>steatosis</keyword>
  <keyword>CAP</keyword>
  <keyword>transient elastography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

